Boehringer creates Shanghai hub to connect with Chinese R&D groups

Boehringer Ingelheim has opened a site in Shanghai to connect its R&D, business development and venture capital groups to Chinese drug developers. The site brings together all the units involved in the identification and support of promising drug development projects.